Innovative BioTherapies, Inc, Ann Arbor, MI 48108, USA.
Transl Res. 2010 Sep;156(3):161-8. doi: 10.1016/j.trsl.2010.07.005. Epub 2010 Jul 30.
Acute and chronic renal failure are disorders with high rates of morbidity and mortality. Current treatment is based upon conventional dialysis to provide volume regulation and small solute clearance. There is growing recognition that renal failure is a complex disease state requiring a multifactorial therapy to address the short-comings of the conventional monofactorial approach. Kidney transplantation remains the most effective treatment, however, organ availability lags far behind demand. Many key kidney functions including gluconeogenesis, ammoniagenesis, metabolism of glutathione, catabolism of important peptide hormones, growth factors, and cytokines critical to multiorgan homeostasis and immunomodulation are provided by renal tubule cells. Therefore, cell-based therapies are promising multifactorial treatment approaches. In this review, current stem cell technologies including adult stem cells, embryonic stem cells and induced pluripotent stem cells will be discussed as cell sources for the treatment of acute and chronic renal failure.
急性和慢性肾衰竭是发病率和死亡率都很高的疾病。目前的治疗方法是基于常规透析来提供容量调节和小分子清除。越来越多的人认识到，肾衰竭是一种复杂的疾病状态，需要采用多因素治疗来解决传统单因素方法的不足之处。肾移植仍然是最有效的治疗方法，然而，器官的供应远远落后于需求。许多关键的肾脏功能，包括糖异生、氨生成、谷胱甘肽代谢、重要肽类激素、生长因子和细胞因子的分解代谢，这些对多器官稳态和免疫调节都很重要，都是由肾小管细胞提供的。因此，基于细胞的治疗是一种很有前途的多因素治疗方法。在这篇综述中，将讨论当前的干细胞技术，包括成体干细胞、胚胎干细胞和诱导多能干细胞，作为治疗急性和慢性肾衰竭的细胞来源。
